|
CN112239495A
|
|
Stable TCR structure and applications
|
|
WO2021078219A1
|
|
Novel anti-cd47 antibodies and uses thereof
|
|
WO2021057930A1
|
|
A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
|
|
WO2021057836A1
|
|
Novel anti-pd-l1 antibodies
|
|
WO2021036929A1
|
|
Humanized antibodies against pd-l1
|
|
WO2021013068A1
|
|
Polypeptide complex for conjugation and use thereof
|
|
WO2021008559A1
|
|
Bispecific antibodies against pd-1 and lag-3
|
|
CN112206327A
|
|
Preparation of antibody coupling drug and high-throughput screening method thereof
|
|
CN111726586A
|
|
Production system operation standard monitoring and reminding system
|
|
WO2020238918A1
|
|
A raman spectroscopy integrated perfusion cell culture system for monitoring and auto-controlling perfusion cell culture
|
|
WO2020216348A1
|
|
Bispecific antibodies against pd-1 and lag-3
|
|
WO2020192709A1
|
|
Novel bispecific polypeptide complexes
|
|
TW202045540A
|
|
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
TW202030206A
|
|
Novel bispecific cd3/cd20 polypeptide complexes
|
|
CN111018969A
|
|
Method for purifying bispecific antibody by light chain select combined chromatography
|
|
CN110982839A
|
|
Method for biotin labeling protein at cellular level
|
|
WO2020125757A1
|
|
A method for improving aggregate removal by protein a chromatography
|
|
WO2020119792A1
|
|
Humanized antibodies against ox40, method for preparing the same, and use thereof
|
|
WO2020119793A1
|
|
Humanized antibodies against ox40, method for preparing the same, and use thereof
|
|
WO2020119789A1
|
|
Fully human antibodies against ox40, method for preparing the same, and use thereof
|
